These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 24417966)

  • 21. Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors.
    Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonosoff GP; Ravin NV
    BMC Biotechnol; 2015 May; 15():42. PubMed ID: 26022390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli.
    Wang W; Huang B; Jiang T; Wang X; Qi X; Gao Y; Tan W; Ruan L
    PLoS One; 2012; 7(12):e52488. PubMed ID: 23285063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice.
    Wang Y; Deng L; Gonzalez GX; Luthra L; Dong C; Ma Y; Zou J; Kang SM; Wang BZ
    Adv Healthc Mater; 2020 Jan; 9(2):e1901176. PubMed ID: 31840437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge.
    Karch CP; Li J; Kulangara C; Paulillo SM; Raman SK; Emadi S; Tan A; Helal ZH; Fan Q; Khan MI; Burkhard P
    Nanomedicine; 2017 Jan; 13(1):241-251. PubMed ID: 27593488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W; Huang B; Wang X; Tan W; Ruan L
    Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch.
    Quan FS; Kim YC; Song JM; Hwang HS; Compans RW; Prausnitz MR; Kang SM
    Clin Vaccine Immunol; 2013 Sep; 20(9):1433-9. PubMed ID: 23863506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza.
    Littauer EQ; Mills LK; Brock N; Esser ES; Romanyuk A; Pulit-Penaloza JA; Vassilieva EV; Beaver JT; Antao O; Krammer F; Compans RW; Prausnitz MR; Skountzou I
    J Control Release; 2018 Apr; 276():1-16. PubMed ID: 29496540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.
    Kolpe A; Schepens B; Ye L; Staeheli P; Saelens X
    Antiviral Res; 2018 Oct; 158():244-254. PubMed ID: 30179634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.
    Deng L; Kim JR; Chang TZ; Zhang H; Mohan T; Champion JA; Wang BZ
    Virology; 2017 Sep; 509():82-89. PubMed ID: 28622575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice.
    Ameghi A; Pilehvar-Soltanahmadi Y; Baradaran B; Barzegar A; Taghizadeh M; Zarghami N; Aghaiypour K
    Viral Immunol; 2016 May; 29(4):228-34. PubMed ID: 27058011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors.
    Petukhova NV; Gasanova TV; Stepanova LA; Rusova OA; Potapchuk MV; Korotkov AV; Skurat EV; Tsybalova LM; Kiselev OI; Ivanov PA; Atabekov JG
    Curr Pharm Des; 2013; 19(31):5587-600. PubMed ID: 23394564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced Immune Responses Conferring Cross-Protection by Skin Vaccination With a Tri-Component Influenza Vaccine Using a Microneedle Patch.
    Zhu W; Li S; Wang C; Yu G; Prausnitz MR; Wang BZ
    Front Immunol; 2018; 9():1705. PubMed ID: 30105019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles.
    Quan FS; Kim YC; Compans RW; Prausnitz MR; Kang SM
    J Control Release; 2010 Nov; 147(3):326-32. PubMed ID: 20692307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.
    Zhao G; Sun S; Du L; Xiao W; Ru Z; Kou Z; Guo Y; Yu H; Jiang S; Lone Y; Zheng BJ; Zhou Y
    Virol J; 2010 Jul; 7():151. PubMed ID: 20624292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.
    Chowdhury MY; Seo SK; Moon HJ; Talactac MR; Kim JH; Park ME; Son HY; Lee JS; Kim CJ
    Virol J; 2014 Feb; 11():21. PubMed ID: 24502341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
    Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-di-GMP with influenza vaccine showed enhanced and shifted immune responses in microneedle vaccination in the skin.
    Shin JH; Lee JH; Jeong SD; Noh JY; Lee HW; Song CS; Kim YC
    Drug Deliv Transl Res; 2020 Jun; 10(3):815-825. PubMed ID: 32141036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles.
    Lee YT; Kim KH; Ko EJ; Kim MC; Lee YN; Hwang HS; Lee Y; Jung YJ; Kim YJ; Santos J; Perez DR; Kang SM
    Virology; 2019 Mar; 529():111-121. PubMed ID: 30685658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
    Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
    Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.